SAB Biotherapeutics Financials
| SABS Stock | USD 3.13 0.06 1.95% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.72 | 5.4476 |
|
|
The essential information of the day-to-day investment outlook for SAB Biotherapeutics includes many different criteria found on its balance sheet. An individual investor should monitor SAB Biotherapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in SAB Biotherapeutics.
Net Income |
|
SAB | Select Account or Indicator |
Understanding current and past SAB Biotherapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of SAB Biotherapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in SAB Biotherapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in SAB Biotherapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of SAB Biotherapeutics. Check SAB Biotherapeutics' Beneish M Score to see the likelihood of SAB Biotherapeutics' management manipulating its earnings.
SAB Biotherapeutics Stock Summary
SAB Biotherapeutics competes with Processa Pharmaceuticals, Third Harmonic, Anebulo Pharmaceuticals, Cadrenal Therapeutics,, and Monopar Therapeutics. SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. The company was founded in 2014 and is based in Sioux Falls, South Dakota. Sab Biotherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US78397T1034 |
| CUSIP | 78397T103 089115109 78397T202 |
| Location | Florida; U.S.A |
| Business Address | 777 W 41st |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.sabbiotherapeutics.com |
| Phone | 605 679 6980 |
| Currency | USD - US Dollar |
SAB Biotherapeutics Key Financial Ratios
| Return On Equity | -1.75 | ||||
| Operating Margin | (34.23) % | ||||
| Price To Sales | 19.10 X | ||||
| Revenue | 2.24 M | ||||
| Gross Profit | (12.53 M) |
SAB Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining SAB Biotherapeutics's current stock value. Our valuation model uses many indicators to compare SAB Biotherapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across SAB Biotherapeutics competition to find correlations between indicators driving SAB Biotherapeutics's intrinsic value. More Info.SAB Biotherapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, SAB Biotherapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value SAB Biotherapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.SAB Biotherapeutics Systematic Risk
SAB Biotherapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. SAB Biotherapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on SAB Biotherapeutics correlated with the market. If Beta is less than 0 SAB Biotherapeutics generally moves in the opposite direction as compared to the market. If SAB Biotherapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one SAB Biotherapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of SAB Biotherapeutics is generally in the same direction as the market. If Beta > 1 SAB Biotherapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in SAB Biotherapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various SAB Biotherapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of SAB Biotherapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
SAB Biotherapeutics November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of SAB Biotherapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of SAB Biotherapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of SAB Biotherapeutics based on widely used predictive technical indicators. In general, we focus on analyzing SAB Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build SAB Biotherapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 6.73 | |||
| Information Ratio | 0.0496 | |||
| Maximum Drawdown | 45.73 | |||
| Value At Risk | (11.25) | |||
| Potential Upside | 17.06 |
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.